Supplementary Figure from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or Without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

Alberto A. Chiappori,Ben Creelan,Tawee Tanvetyanon,Jhanelle E. Gray,Eric B. Haura,Ram Thapa,Margaret L. Barlow,Zhihua Chen,Dung Tsa Chen,Amer A. Beg,Theresa A. Boyle,Julio Castro,Liza Morgan,Erick Morris,Mehreteab Aregay,Felipe K. Hurtado,Luigi Manenti,Scott Antonia

pubmed（2023）

引用 22|浏览26

暂无评分

摘要

Supplementary Figure from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

查看译文

关键词

Adenosine Receptors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要